FDA approves first flu vaccine that can be self-administered at home
FluMist is a nasal spray manufactured by AstraZeneca that has been used to protect against influenza in the United States ...
FDA approves first self-administered flu vaccine
The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007, was first approved by the FDA in 2003 for individuals between five and 49 years of age. Its approval has ...
devdiscourse12h
Latest Health Developments: Key Approvals and Controversies
Recent health developments include the EU backing Novo Nordisk's Wegovy for obesity-related heart conditions, FDA approvals ...
At-home nasal spray flu vaccine to be available in fall of 2025
The FDA Friday approved the flu vaccine that can be done at home and does not need to be administered by a health care provider.
FDA approves at-home flu vaccine
The FDA is clearing the way for an at-home flu vaccines. A self-administered version of pharmaceutical giant AstraZeneca’s ...
No Doctor Necessary: US Okays Nasal Spray Flu Vaccine For Self-use
No doctor? No problem. In a first, the US Food and Drug Administration on Friday approved a nasal spray flu vaccine for self-administration. Starting next fall, AstraZeneca's FluMist, which was ...
FDA approves first nasal spray flu vaccine for use at home
The Food and Drug Administration on Friday approved the first at-home flu vaccine, a nasal spray that consumers with a ...
AstraZeneca PLC ADR falls Friday, underperforms market
The AstraZeneca PLC ADR AZN slumped 0.66% to $78.38 Friday, on what proved to be an all-around mixed trading session for the ...
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...
AstraZeneca PLC ADR outperforms market on strong trading day
The AstraZeneca PLC ADR AZN inched 0.06% higher to $78.58 Wednesday, on what proved to be an all-around dismal trading ...
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...
Buy3d
AstraZeneca Fasenra treatment for EGPA approved in the US
Approximately half of EGPA patients also have adult-onset severe eosinophilic asthma, or SEA, for which Fasenra is only the second biologic approved treatment. Fasenra is now approved as an add-on ...